New Delhi, 26May 2026: Tata 1mg, India’s largest integrated digital healthcare platform, ended FY26 as one of the only eHealth companies in India to turn EBITDA positive across all established lines of business — a milestone that strongly positions the company among a select group of healthcare companies of this scale in India.

The performance marks the culmination of a decade of building an integrated healthcare model that few players in India have attempted across these many verticals simultaneously.

“This year has been a real inflection point. All our core businesses turned EBITDA positive in December and sustained that momentum through Q4. This is the outcome of a decade of building an integrated healthcare model — and we are now seeing that model compound, with scale translating into both better customer experience and stronger unit economics,” said Prashant Tandon, Co-Founder and CEO, Tata 1mg.

Tata 1mg’s growth in FY26 is driven by strong performance across each of its verticals. The company’s ePharmacy business, currently ranked #1 in India, achieved breakeven while continuing to scale, with express pharmacy delivery in 30-60 minutes now live across 10 cities. 

In diagnostics, Tata 1mg has entered the select group of pathology players in India operating at the ₹500-1,000 crore scale. The business grew at over 40% year-on-year during FY26, sustaining double-digit EBITDA margins. The company’s 19 NABL-accredited labs now serve customers across 70 cities, with its National Reference Lab holding CAP accreditation.

Tata 1mg’s Specialty Pharma vertical, where the company holds a leading position across Patient Support Programs, Adult Vaccination, Cancer Care, and Obesity Management, posted ~65% growth during the year. The company’s D2C health product range similarly crossed ₹200 crore ARR and has remained profitable since inception.

On the offline front, Tata 1mg now operates 280+ brick-and-mortar stores across 9 clusters. The company plans to scale its retail footprint to 500+ stores over the next 12 months as part of its broader omnichannel expansion strategy.

“We operate in a very large market, where despite being a top player, we are not even 1% of the total market still. This gives us tremendous confidence and excitement as we work towards the phase ahead. Our vision is to build India's most trusted integrated, omnichannel healthcare platform.” added Tandon.

Alongside its commercial milestones, the company continues to invest in technology and AI as a core competitive differentiator. Its Health Insights Hub, along with capabilities like Family Hub, are enabling a more comprehensive and longitudinal view of consumer health, driving more personalized, predictive, and preventive healthcare experiences and outcomes. The company’s AI-powered insights platform, Pulse, is now being actively used by over 75 pharmaceutical companies, reflecting Tata 1mg’s growing role as a health intelligence provider to the broader Indian pharma ecosystem.

Looking ahead, Tata 1mg’s expansion over the next 12 to 24 months will be anchored on a cluster-driven strategy, bringing all its services together across key geographies and deepening its integrated supply chain. The company has identified faster pharmacy deliveries, diagnostics expansion into radiology and specialized tests, institutional partnerships in specialty care, and AI-first personalization as the primary growth enablers for FY27 and beyond.

“We see healthcare evolving towards being more personalized, predictive, and preventive — with trust at its core. Over the next three to five years, we aim to build India’s most trusted integrated, omnichannel healthcare platform and play a meaningful role in enabling that shift,” Tandon said.